APA (7th ed.) Citation

Miranda, L., Rossini, N., Lima, K., Pereir-Martins, D., Schuringa, J., Rego, E., . . . Machad-Neto, J. (2023, October). AD80 HAS HIGHER POTENCY COMPARED TO CLINICALLY USED FLT3 INHIBITORS IN FLT3-ITD AML CELLS. Hematology, Transfusion and Cell Therapy.

Chicago Style (17th ed.) Citation

Miranda, LBL, NO Rossini, K. Lima, DA Pereir-Martins, JJ Schuringa, EM Rego, F. Traina, MVB Dias, and JA Machad-Neto. "AD80 HAS HIGHER POTENCY COMPARED TO CLINICALLY USED FLT3 INHIBITORS IN FLT3-ITD AML CELLS." Hematology, Transfusion and Cell Therapy Oct. 2023.

MLA (9th ed.) Citation

Miranda, LBL, et al. "AD80 HAS HIGHER POTENCY COMPARED TO CLINICALLY USED FLT3 INHIBITORS IN FLT3-ITD AML CELLS." Hematology, Transfusion and Cell Therapy, Oct. 2023.